---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-031574"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2025-10-23T23:59:59+00:00"
generated_at: "2026-05-17T02:31:09.421241+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Moleculin announces investigator-initiated Phase 1B/2 study of Annamycin for pancreatic cancer

## Summary
- Phase 1B/2 single-arm study of Annamycin for third-line advanced pancreatic cancer; investigator-initiated by Atlantic Health.
- Moleculin supplies Annamycin and maintains IND; Dr. Angela Alistar (Atlantic Health) is principal investigator.
- Estimated additional cost to Moleculin ~$1M from 2026 to 2030 for drug supply and testing.
- Preclinical data shows Annamycin targets topoisomerase II, correlated with poor survival in pancreatic cancer.
- Annamycin (naxtarubicin) has Fast Track and Orphan Drug status for AML; Orphan Drug for STS lung mets.

## SEC filing metadata
- accession: 0001437749-25-031574
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2025-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774925031574/0001437749-25-031574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774925031574/mbrx20251020_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-031574
- JSON: https://secwatch.observer/filing/0001437749-25-031574.json
- Plain text: https://secwatch.observer/filing/0001437749-25-031574.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.